$1.31
-0.0400 (-2.96%)
At Close: Jul 31, 2026
Alzamend Neuro Reports Third Fiscal Quarter Financial Results and Provides a Business Update
08:00am, Thursday, 16'th Mar 2023
ATLANTA--(BUSINESS WIRE)--Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’
Alzamend Neuro to Present at Sequire Biotechnology Conference
08:00am, Thursday, 26'th Jan 2023
ATLANTA--(BUSINESS WIRE)--Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disea
ATLANTA--(BUSINESS WIRE)--Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’
ATLANTA--(BUSINESS WIRE)--Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’
Alzamend Neuro CEO Stephan Jackman to Appear on Fox Business Network to Discuss Therapeutic Pipeline
08:00am, Tuesday, 15'th Nov 2022
ATLANTA--(BUSINESS WIRE)--Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’
ATLANTA--(BUSINESS WIRE)--Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’
Alzamend Neuro Announces Addition of Healthy Subjects to Ongoing Phase IIA Clinical Trial for AL001 in Alzheimer’s Subjects
08:00am, Wednesday, 05'th Oct 2022
ATLANTA--(BUSINESS WIRE)--Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’
ATLANTA--(BUSINESS WIRE)--Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’
4 Alzheimer's Penny Stocks To Watch After Biogen Stock Explodes
10:56am, Wednesday, 28'th Sep 2022
Penny stocks to buy [or avoid] after Biogen Alzheimer's news. The post 4 Alzheimer's Penny Stocks To Watch After Biogen Stock Explodes appeared first on Penny Stocks to Buy, Picks, News and Informatio
3 Penny Stocks to Add to Your Watchlist This Coming Week
08:54pm, Friday, 13'th May 2022
Which penny stocks are you watching right now? The post 3 Penny Stocks to Add to Your Watchlist This Coming Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Alzamend Neuro Inc Shares Close in on 52-Week Low - Market Mover
08:02am, Saturday, 15'th Jan 2022 Kwhen Finance
Alzamend Neuro Inc (ALZN) shares closed today at 1.1% above its 52 week low of $1.77, giving the company a market cap of $163M. The stock is currently down 3.2% year-to-date, down 86.4% over the past 12 months, and down 86.4% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 0.7%. Trading Activity Trading volume this week was 7.4% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 3.0% lower than its 5-day moving average, 11.5% lower than its 20-day moving average, and 22.4% lower than its 90-day moving average.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 1213.7% The company's stock price performance over the past 12 months lags the peer average by 445.4%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.
Are These Penny Stocks Worth Buying Right Now?
07:45pm, Tuesday, 04'th Jan 2022
Can penny stocks continue to show positive momentum in 2022? The post Are These Penny Stocks Worth Buying Right Now?
Here's 3 Top Penny Stocks For Your January Watchlist
06:30pm, Sunday, 19'th Dec 2021
Can penny stocks continue to show momentum next year? The post Here's 3 Top Penny Stocks For Your January Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com
Alzamend: Biotech To Watch With 2 Drugs Targeting Multi-Billion Dollar Alzheimer's Market
11:59pm, Friday, 17'th Dec 2021
Alzamend reported positive results from its phase 1 study using AL001 for the treatment of patients with Alzheimer's Disease.
Why Alzamend Neuro Stock Soared Today
06:35pm, Tuesday, 14'th Dec 2021
The company hopes to advance the standard of care for people with dementia.
Sign In
Buy ALZN